Advertisement

Annals of Surgical Oncology

, Volume 23, Supplement 5, pp 634–641 | Cite as

Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic

  • Amar U. Kishan
  • Caitlin L. Gomez
  • Nicole A. Dawson
  • Robyn Dvorak
  • Nova M. Foster
  • Anne Hoyt
  • Sara A. Hurvitz
  • Amy Kusske
  • Erica L. Silver
  • Charles Tseng
  • Susan A. McCloskey
Breast Oncology

Abstract

Background

Findings show that 5–10 % of women with a diagnosis of breast cancer (BCa) have actionable genetic mutations. The National Comprehensive Cancer Network guidelines for testing to detect BRCA1/2 mutations include personal history (PH) variables such as age of 45 years or younger and a family history (FH) variables. Rates of FH documentation and overall rates of appropriate referral for genetic testing are low, ranging from about 30 to 60 %. The authors hypothesized that an upfront FH documentation and inclusion of a genetics counselor in a multidisciplinary clinic (MDC) setting would increase rates of appropriate referral for genetic testing.

Methods

The study enrolled 609 consecutive women with non-metastatic BCa seen in consultation between June 2012 and December 2015 at a multidisciplinary clinic. Rates of FH documentation and referral for genetic testing to detect BRCA1/2 mutations were assessed before and after inclusion of a genetic counselor in the MDC.

Results

The rates of FH documentation and appropriate referral were 100 and 89 %, respectively. Half (50 %) of the patients had only FH-based indications for testing. All the patients with PH-based indications were referred. The inclusion of a genetic counselor significantly increased appropriate referral rates among those with only FH-based indications (62 vs. 92 %) and overall (80 vs. 96 %) (p < 0.0001 for both). Among the 12 % of the patients with actionable mutations, 60 % were 45 years of age or younger, whereas 30 % had only FH-based testing indications.

Conclusions

This report shows substantially higher FH documentation and appropriate genetic testing rates than prior reports. Many patients with indications for genetic testing may have only FH-based indications for testing, and this subset may account for the sizable proportion of patients with newly diagnosed BCa who have actionable mutations.

Keywords

Genetic Testing Genetic Counselor National Comprehensive Cancer Network National Comprehensive Cancer Network Referral Rate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Disclosure

None

Supplementary material

10434_2016_5545_MOESM1_ESM.docx (17 kb)
Supplementary material 1 (DOCX 16 kb)

References

  1. 1.
    Foulkes WD. Inherited susceptibility to common cancers. N Engl J Med. 2008;359:2143–53.CrossRefPubMedGoogle Scholar
  2. 2.
    Lokich E, Stuckey A, Raker C, Wilbur JS, Laprise J, Gass J. Preoperative genetic testing affects surgical decision making in breast cancer patients. Gynecol Oncol. 2014;134:326–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Schwartz GF, Hughes KS, Lynch HT, et al. Proceedings of the international consensus conference on breast cancer risk, genetics, & risk management, April 2007. Cancer. 2008;113:2627–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA. Polygenic susceptibility to breast cancer and implications for prevention. Nat Genet. 2002;31:33–6.CrossRefPubMedGoogle Scholar
  5. 5.
    Moyer VA. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: US Preventive Services Task Force recommendation statement. Ann Intern Med. 2014;160:271–81.PubMedGoogle Scholar
  6. 6.
    Ford D, Easton DF, Stratton M, et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet. 1998;62:676–89.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    NCCN. NCCN clinical practice guidelines in oncology: genetic/familial high-risk assessment: breast and ovarian, v2.2016. NCCN.Google Scholar
  8. 8.
    Rosenberg SM, Ruddy KJ, Tamimi RM, et al. BRCA1 and BRCA2 mutation testing in young women with breast cancer. JAMA Oncol. 2016;2:730–6.CrossRefPubMedGoogle Scholar
  9. 9.
    Kehl KL, Shen C, Litton JK, Arun B, Giordano SH. Rates of BRCA1/2 mutation testing among young survivors of breast cancer. Breast Cancer Res Treat. 2016;155:165–73.CrossRefPubMedGoogle Scholar
  10. 10.
    Anderson B, McLosky J, Wasilevich E, Lyon-Callo S, Duquette D, Copeland G. Barriers and facilitators for utilization of genetic counseling and risk assessment services in young female breast cancer survivors. J Cancer Epidemiol. 2012;2012:11.CrossRefGoogle Scholar
  11. 11.
    Cragun D, Bonner D, Kim J, et al. Factors associated with genetic counseling and BRCA testing in a population-based sample of young Black women with breast cancer. Breast Cancer Res Treat. 2015;151:169–76.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Febbraro T, Robison K, Wilbur JS, et al. Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol. 2015;138:109–14.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Levy DE, Byfield SD, Comstock CB, et al. Underutilization of BRCA1/2 testing to guide breast cancer treatment: Black and Hispanic women particularly at risk. Genet Med. 2011;13:349–55.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    McCarthy AM, Bristol M, Fredricks T, et al. Are physician recommendations for BRCA1/2 testing in patients with breast cancer appropriate? A population-based study. Cancer. 2013;119:3596–603.PubMedGoogle Scholar
  15. 15.
    Powell CB, Littell R, Hoodfar E, Sinclair F, Pressman A. Does the diagnosis of breast or ovarian cancer trigger referral to genetic counseling? Int J Gynecol Cancer. 2013;23:431–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Wood ME, Kadlubek P, Pham TH, et al. Quality of cancer family history and referral for genetic counseling and testing among oncology practices: a pilot test of quality measures as part of the American Society of Clinical Oncology Quality Oncology Practice Initiative. J Clin Oncol. 2014;32:824–9.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Stuckey A, Febbraro T, Laprise J, Wilbur JS, Lopes V, Robison K. Adherence patterns to National Comprehensive Cancer Network guidelines for referral of women with breast cancer to genetics professionals. Am J Clin Oncol. 2014;39:363–7.CrossRefGoogle Scholar
  18. 18.
    Murff HJ, Byrne D, Syngal S. Cancer risk assessment: quality and impact of the family history interview. Am J Prev Med. 2004;27:239–45.PubMedGoogle Scholar
  19. 19.
    Flynn BS, Wood ME, Ashikaga T, Stockdale A, Dana GS, Naud S. Primary care physicians’ use of family history for cancer risk assessment. BMC Fam Pract. 2010;11:45.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Grover S, Stoffel EM, Bussone L, Tschoegl E, Syngal S. Physician assessment of family cancer history and referral for genetic evaluation in colorectal cancer patients. Clin Gastroenterol Hepatol. 2004;2:813–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Acton RT, Burst NM, Casebeer L, et al. Knowledge, attitudes, and behaviors of Alabama’s primary care physicians regarding cancer genetics. Acad Med. 2000;75:850–2.CrossRefPubMedGoogle Scholar
  22. 22.
    Wilkins-Haug L, Erickson K, Hill L, Power M, Holzman GB, Schulkin J. Obstetrician-gynecologists’ opinions and attitudes on the role of genetics in women’s health. J Women Health Gend Based Med. 2000;9:873–9.CrossRefGoogle Scholar
  23. 23.
    Decker G, Murtz P, Gieseke J, et al. Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T. Radiother Oncol. 2014;113:115–20.CrossRefPubMedGoogle Scholar
  24. 24.
    Haidle JL . Important differences between a triage pedigree and risk assessment. J Clin Oncol. 2014;32:3345–6.CrossRefGoogle Scholar
  25. 25.
    Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117–30.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    NCCN. NCCN clinical practice guidelines in oncology: breast cancer, v2.2016. NCCN.Google Scholar
  27. 27.
    Schwartz MD, Lerman C, Brogan B, et al. Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients. J Clin Oncol. 2004;22:1823–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Weitzel JN, McCaffrey SM, Nedelcu R, MacDonald DJ, Blazer KR, Cullinane CA. Effect of genetic cancer risk assessment on surgical decisions at breast cancer diagnosis. Arch Surg. 2003;138:1323–8, (discussion 1329).CrossRefPubMedGoogle Scholar
  29. 29.
    Garcia C, Wendt J, Lyon L, et al. Risk management options elected by women after testing positive for a BRCA mutation. Gynecol Oncol. 2014;132:428–33.CrossRefPubMedGoogle Scholar
  30. 30.
    Livraghi L, Garber JE. PARP inhibitors in the management of breast cancer: current data and future prospects. BMC Med. 2015;13:188.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Rich EC, Burke W, Heaton CJ, et al. Reconsidering the family history in primary care. J Gen Intern Med. 2004;19:273–80.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    King MC, Levy-Lahad E, Lahad A. Population-based screening for BRCA1 and BRCA2: 2014 Lasker Award. JAMA. 2014;312:1091–2.CrossRefPubMedGoogle Scholar
  33. 33.
    Long EF, Ganz PA. Cost-effectiveness of universal BRCA1/2 screening: evidence-based decision making. JAMA Oncol. 2015;1:1217–8.CrossRefPubMedGoogle Scholar
  34. 34.
    Kaplan CP, Haas JS, Perez-Stable EJ, Des Jarlais G, Gregorich SE. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005;41:7–15.CrossRefPubMedGoogle Scholar
  35. 35.
    Trivers KF, Baldwin LM, Miller JW, et al. Reported referral for genetic counseling or BRCA1/2 testing among United States physicians: a vignette-based study. Cancer. 2011;117:5334–43.CrossRefPubMedGoogle Scholar
  36. 36.
    Van Riel E, Warlam-Rodenhuis CC, Verhoef S, Rutgers EJ, Ausems MG. BRCA testing of breast cancer patients: medical specialists’ referral patterns, knowledge, and attitudes to genetic testing. Eur J Cancer Care Engl. 2010;19:369–76.CrossRefPubMedGoogle Scholar
  37. 37.
    Schlich-Bakker KJ, Ausems MG, Schipper M, Ten Kroode HF, Warlam-Rodenhuis CC, van den Bout J. BRCA1/2 mutation testing in breast cancer patients: a prospective study of the long-term psychological impact of approach during adjuvant radiotherapy. Breast Cancer Res Treat. 2008;109:507–14.CrossRefPubMedGoogle Scholar
  38. 38.
    Schlich-Bakker KJ, Warlam-Rodenhuis CC, van Echtelt J, van den Bout J, Ausems MG, ten Kroode HF. Short-term psychological distress in patients actively approached for genetic counselling after diagnosis of breast cancer. Eur J Cancer. 2006;42:2722–8.CrossRefPubMedGoogle Scholar
  39. 39.
    Ralph J, Coates P. Counseling US women on BRCA testing, a new healthy people 2020 objective: findings from the national health interview survey, 2000–2005. Lansing, MI: Michigan. Department of Community Health Promoting Cancer Genomics Best Practives Steering Committee. 2010.Google Scholar
  40. 40.
    Christie J, Quinn GP, Malo T, et al. Cognitive and psychological impact of BRCA genetic counseling in before and after definitive surgery breast cancer patients. Ann Surg Oncol. 2012;19:4003–11.CrossRefPubMedGoogle Scholar
  41. 41.
    Desmond A, Kurian AW, Gabree M, et al. Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncol. 2015;1:943–51.CrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2016

Authors and Affiliations

  • Amar U. Kishan
    • 1
  • Caitlin L. Gomez
    • 1
  • Nicole A. Dawson
    • 2
  • Robyn Dvorak
    • 3
  • Nova M. Foster
    • 4
  • Anne Hoyt
    • 5
  • Sara A. Hurvitz
    • 6
  • Amy Kusske
    • 4
  • Erica L. Silver
    • 3
  • Charles Tseng
    • 7
  • Susan A. McCloskey
    • 1
  1. 1.Department of Radiation OncologyUniversity of CaliforniaLos AngelesUSA
  2. 2.Department of Pathology and Laboratory MedicineUniversity of CaliforniaLos AngelesUSA
  3. 3.Santa Monica-UCLA Breast CenterUniversity of CaliforniaLos AngelesUSA
  4. 4.Department of Surgery, Division of General SurgeryUniversity of CaliforniaLos AngelesUSA
  5. 5.Department of RadiologyUniversity of CaliforniaLos AngelesUSA
  6. 6.Department of Hematology and OncologyUniversity of CaliforniaLos AngelesUSA
  7. 7.Department of Plastic SurgeryUniversity of CaliforniaLos AngelesUSA

Personalised recommendations